Sep 16, 2013 | Health Tips, Research, Your Health
Ovarian cancer is a heterogeneous and rapidly progressive disease of low prevalence and poor survival. In the United States the number of deaths attributed to ovarian cancer approximates that of all other gynecologic malignancies combined. Unfortunately, the majority (75%) of women diagnosed with ovarian carcinoma continue to have advanced stage disease (Stage III/ IV), with widespread metastases throughout the peritoneal cavity, lymph nodes, liver or lungs. Presently less than 20% of women with ovarian cancers are detected when the cancer is still confined to the ovary (Stage I).
(more…)
Sep 15, 2013 | Research, Your Health
Glioblastoma (GBM) is the most common and most aggressive brain tumor, known to be a highly invasive and rapidly spreading disease. Even with aggressive treatment such as surgery, radiation, and chemotherapy, they are almost always incurable.
The Mount Sinai Comprehensive Brain Tumor Program is pioneering the use of electrical tumor treating fields to be used with conventional therapy. The device, manufactured by Novocure, is called NovoTTF and it is FDA approved for recurrent GBM. It consists of a head cap that produces changes in electrical fields, which is worn continuously.
(more…)
Sep 3, 2013 | Research, School, Your Health
Today’s standard therapies for cancer exist because people have participated in clinical trials – yet choosing to participate in a cancer clinical trial is an important personal decision that can be intimidating for many patients. In order to better help patients understand cancer clinical trials, the reasons to participate in them, and clinical research at Mount Sinai, The Tisch Cancer Institute has released a new video, “Clinical Trials at Mount Sinai: Moving the Field Forward.”
(more…)
Updated on Jun 30, 2022 | Neuroscience, Research, School
Multiple Sclerosis is an inflammatory demyelinating disorder of the Central Nervous System of debated etiology. While there is general consensus regarding the role of an active immune system in myelin destruction, the questions related to the initial events triggering immune system involvement remain unanswered and the identity of disease course modifiers is only partially understood. Epidemiological studies have suggested the possibility that disease onset and course are the result of an interaction between genetic susceptibility and environmental factors, though much remains to be learned about the identity of the environmental factors and whether they can be modified. Among the proposed variables affecting MS are geographic location, smoking, vitamin D levels and the much debated diet and infections.
(more…)
Updated on Jun 30, 2022 | Research, Your Health
Drug-induced liver injury (DILI) is the single most common reason for regulatory actions concerning drugs, including failure to gain approval for marketing, removal from the market place and restriction of prescribing indications.
DILI is also a significant cause of morbidity and mortality in many patient populations. Due to its idiosyncratic nature, variable presentation and the vast number of potential causative drugs as well as herbal and dietary supplements, DILI is often diagnosed late in its course when patients have severe liver disease. DILI, including acute liver failure requiring liver transplantation, can happen anytime to anyone taking medications, even over the counter medications. Unfortunately, there are no tests to predict who is at risk nor to diagnose this problem. (more…)
Updated on Jun 30, 2022 | Inside, Research, Your Health
Significant advances in science are taking place, but translating them into clinical treatments for an array of human diseases is being hampered by public policies that are not aligned with the public good. That observation was articulated by Kenneth L. Davis, MD, President and Chief Executive Officer of The Mount Sinai Medical Center, during a discussion on “What’s Holding Back Medical Progress?,” one of three talks in which he participated at the ninth annual Aspen Ideas Festival, in Colorado, which ran from June 26 – July 2.
(more…)
